Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3048% below fair value
$2.96−0.17 (-5.43%)
Close on Nov 12, 2026Market cap $238.49MP/E 11.8Yield –
Protalix BioTherapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Protalix BioTherapeutics's enterprise value was $227.62M on Nov 11, 2026, against $139.00M a year earlier. Over the last 5 years it ranged from -$762.97K to $227.62M, with a median of $87.24M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $227.62M | +61.8% |
| 2025 | Dec 31, 2025 | $140.71M | +17.0% |
| 2024 | Dec 31, 2024 | $120.24M | +17.6% |
| 2023 | Dec 29, 2023 | $102.24M | +90.6% |
| 2022 | Dec 30, 2022 | $53.65M | +128.2% |
| 2021 | Dec 31, 2021 | $23.51M | -44.9% |
| 2020 | Dec 31, 2020 | $42.64M | +56.6% |
| 2019 | Dec 31, 2019 | $27.22M | -99.8% |
| 2018 | Dec 31, 2018 | $11.25B | +19167.9% |
| 2017 | Dec 29, 2017 | $58.40M | – |
| 2016 | Dec 30, 2016 | -$6.52M | -110.7% |
| 2015 | Dec 31, 2015 | $61.09M | -44.6% |
| 2014 | Dec 31, 2014 | $110.36M | -58.7% |
| 2013 | Dec 31, 2013 | $267.28M | -36.3% |
| 2012 | Dec 31, 2012 | $419.88M | -13.8% |
| 2011 | Jul 29, 2011 | $487.34M | – |
See a number that looks wrong?